UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 263

Sortiert nach

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

JAAD Case Reports, 2024-06, Vol.48, p.18-22

2024

Link zum Volltext

Verfügbarkeit prüfen

Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018–2022): A real‐world, retrospective study

Cancer medicine (Malden, MA), 2024-05, Vol.13 (10), p.e7284-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis

Frontiers in immunology, 2024-04, Vol.15, p.1334899-1334899

2024

Link zum Volltext

Verfügbarkeit prüfen

Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting

Open forum infectious diseases, 2024-04, Vol.11 (4), p.ofae162-ofae162

2024

Link zum Volltext

Verfügbarkeit prüfen

Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation

Cancers, 2024-04, Vol.16 (7), p.1298

2024

Link zum Volltext

Verfügbarkeit prüfen

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge

Pediatric and developmental pathology, 2024-03, p.10935266241230600-10935266241230600

2024

Link zum Volltext

Verfügbarkeit prüfen

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Turkish journal of haematology, 2023-12, Vol.40 (4), p.284-285

2023

Link zum Volltext

Verfügbarkeit prüfen

The pathobiology of select adolescent young adult lymphomas

EJHaem, 2023-11, Vol.4 (4), p.892-901

2023

Link zum Volltext

Verfügbarkeit prüfen

Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy

Diagnostic pathology, 2023-10, Vol.18 (1), p.1-111, Article 111

2023

Link zum Volltext

Verfügbarkeit prüfen

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S54-S56

2023

Link zum Volltext

Verfügbarkeit prüfen

ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S439-S440

2023

Link zum Volltext

Verfügbarkeit prüfen

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas

Frontiers in oncology, 2023-08, Vol.13, p.1278169-1278169

2023

Link zum Volltext

Verfügbarkeit prüfen

Mediastinal Desmoid Tumor Presents as Lymphadenopathy in Patient with Lymphoma: A Case Report

Case reports in oncology, 2023-08, Vol.16 (1), p.765-770

2023

Link zum Volltext

Verfügbarkeit prüfen

Advanced penile lymphoma: Case report and review of the literature

Journal of cancer research and therapeutics, 2023-07, Vol.19 (3), p.823-825

2023

Link zum Volltext

Verfügbarkeit prüfen

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Journal of cellular and molecular medicine, 2023-07, Vol.27 (14), p.1928-1946

2023

Link zum Volltext

Verfügbarkeit prüfen

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

Annals of hematology, 2023-05, Vol.102 (5), p.1159-1169

2023

Link zum Volltext

Verfügbarkeit prüfen

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Future oncology (London, England), 2023-04, Vol.19 (11), p.737-738

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

EJHaem, 2023-02, Vol.4 (1), p.108-114

2023

Link zum Volltext

Verfügbarkeit prüfen

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists

Strahlentherapie und Onkologie, 2023-02, Vol.199 (2), p.115-120

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

Cells (Basel, Switzerland), 2022-12, Vol.11 (24), p.4085

2022

Link zum Volltext

Verfügbarkeit prüfen

A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children’s Cancer Group

Annals of hematology, 2022-09, Vol.101 (9), p.2035-2043

2022

Link zum Volltext

Verfügbarkeit prüfen

Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases

Frontiers in immunology, 2022-08, Vol.13, p.970183-970183

2022

Link zum Volltext

Verfügbarkeit prüfen

Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome

South Asian journal of cancer, 2022-07, Vol.11 (3), p.256-259

2022

Link zum Volltext

Verfügbarkeit prüfen

How we treat NK/T-cell lymphomas

Journal of hematology and oncology, 2022-06, Vol.15 (1), p.74-74, Article 74

2022

Link zum Volltext

Verfügbarkeit prüfen

Giant mesenteric fibromatosis associated with non-Hodgkin lymphoma. A case report and literature review

Acta chirurgica belgica, 2022-06, Vol.122 (3), p.204-210

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 263

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(244)
Mit Volltextzugriff
(239)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(222)
Life Sciences & Biomedicine
(221)
Humans
(209)
Male
(152)
Female
(145)
Oncology
(137)
Middle Aged
(133)
Hematology
(130)
Adult
(121)
Aged
(111)
Lymphoma, Non-Hodgkin - Drug Therapy
(109)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(98)
Treatment Outcome
(81)
Biological And Medical Sciences
(78)
Medical Sciences
(78)
Prognosis
(68)
Adolescent
(64)
Cyclophosphamide - Administration & Dosage
(63)
Lymphoma, Non-Hodgkin - Pathology
(60)
Aggressive Lymphoma
(58)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Tumor flare reaction in a patient with mycosis fungoides treated with a novel immune-epigenetic doublet

Analysis of hepatitis B virus infection in 1424 patients with different pathological types of lymphoma (2018–2022): A real‐world, retrospective study

Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis

Hematological Complications of Human Immunodeficiency Virus (HIV) Infection: An Update From an HIV-Endemic Setting

Copy Number Analysis of 9p24.1 in Classic Hodgkin Lymphoma Arising in Immune Deficiency/Dysregulation

Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge

Effect and Safety of Orelabrutinib and Lenalidomide Plus R-mini CDOP in Relapsed/Refractory Aggressive B-cell Non-Hodgkin Lymphoma

The pathobiology of select adolescent young adult lymphomas

Possible Concomitant Aggressive NK Cell Leukemia and EBV-positive T-cell lymphoma; Using the online beta version of WHO-HAEM5 and videoconferencing software to make diagnoses accessible in an emerging economy

EXABS-140-LYM High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations

ABCL-515 Updated Results of the Safety Run-In of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas

Mediastinal Desmoid Tumor Presents as Lymphadenopathy in Patient with Lymphoma: A Case Report

Advanced penile lymphoma: Case report and review of the literature

Long non‐coding RNA as a novel biomarker and therapeutic target in aggressive B‐cell non‐Hodgkin lymphoma: A systematic review

Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study

The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma

Phase I study of novel SYK inhibitor TAK‐659 (mivavotinib) in combination with R‐CHOP for front‐line treatment of high‐risk diffuse large B‐cell lymphoma

The new German evidence-based guideline on diffuse large B-cell lymphoma—key aspects for radiation oncologists

Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

A prospective multicenter study investigating rituximab combined with intensive chemotherapy in newly diagnosed pediatric patients with aggressive mature B cell non-Hodgkin lymphoma (CCCG-BNHL-2015): a report from the Chinese Children’s Cancer Group

Spectrum and trigger identification of hemophagocytic lymphohistiocytosis in adults: A single-center analysis of 555 cases

Serum Free Light Chain Assay as a Prognostic Marker in Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma: Impact on Survival Outcome

How we treat NK/T-cell lymphomas

Giant mesenteric fibromatosis associated with non-Hodgkin lymphoma. A case report and literature review

Suchergebnisse filtern